Khurram Jamil - 14 Jul 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Reporting relationship: Chief Medical Officer
Issuer ticker: GALT
Reported as of: 14 Jul 2026
Net transaction value: -$83,284
SEC form: 4
Accepted by SEC: 16 Jul 2026, 17:39:50 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: Jack W. Callicutt, by power of attorney

Key filing fact

Khurram Jamil filed Form 4 for GALECTIN THERAPEUTICS INC (GALT) on 16 Jul 2026.

Key facts

This page summarizes Khurram Jamil's Form 4 filing for GALECTIN THERAPEUTICS INC (GALT).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jul 2026, 17:39.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: -$83,284.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002032345 Primary reporting owner

Jamil Khurram

Relationship: Chief Medical Officer
Address: 4960 PEACHTREE INDUSTRIAL BLVD, SUITE 240, NORCROSS
Signature: Jack W. Callicutt, by power of attorney
Signature date: 16 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GALT transaction

Common Stock

Options Exercise

Transaction value
Shares: +16,250
Change %
Price: $3.04^*
Shares after: 16,250
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F1

GALT transaction

Common Stock

Sale

Transaction value: $83,284
Shares: -16,250
Change %: -100%
Price: $5.13
Shares after: 0
Date: 14 Jul 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GALT transaction Derivative

Stock option (right to buy)

Options Exercise

Transaction value
Shares: -16,250
Change %: -25%
Price: $0.000000^*
Shares after: 48,750
Date: 14 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,250
Exercise price: $3.04
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 2, 2026, as disclosed in the Issuers Quarterly Report on Form 10-Q, filed with the SEC on May 15, 2026

Footnote F2

The shares were sold in multiple transactions at prices ranging from $5.00 to $5.32. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

The options vested at a rate of twenty five percent or 16,250 options on each of June 30, 2026; December 31, 2026; June 30, 2027; and December 31, 2027.